Summary of major recommendations for prevention of cytomegalovirus (CMV).
| Type of Prevention . | Rating . |
|---|---|
| Prevention of Exposure | |
| Testing of recipient and donor IgG serostatus | AIII |
| Provision of seronegative or leukocyte-depleted blood to seronegative allograft recipients | AI |
| Counseling of seronegative recipient on transmission mode of CMV | AII |
| Use of latex condoms during sexual contacts in sexually active seronegative recipients not in long-term monogamous relationships | AII |
| Avoiding diaper changes and contact with oral secretions from toddlers or seronegative recipients | AII |
| Preventing Disease and Disease Recurrence | |
| Ganciclovir prophylaxis or preemptive therapy based on pp65 antigenemia or DNA detection between engraftment and day 100 for patients at high risk for CMV disease | AI |
| Preferential use of preemptive therapy based on pp65 antigenemia or DNA detection between engraftment and day 100 in seronegative recipients with a seropositive donor | BII |
| CMV surveillance and preemptive therapy in CMV seropositive recipients of CD34 selected autologous transplants | BII |
| Use of IVIG or CMV-Ig for prevention of CMV infection and disease | DI |
| Use of high-dose acyclovir for prevention of CMV infection and disease in seropositive autograft recipients | DI |
| Type of Prevention . | Rating . |
|---|---|
| Prevention of Exposure | |
| Testing of recipient and donor IgG serostatus | AIII |
| Provision of seronegative or leukocyte-depleted blood to seronegative allograft recipients | AI |
| Counseling of seronegative recipient on transmission mode of CMV | AII |
| Use of latex condoms during sexual contacts in sexually active seronegative recipients not in long-term monogamous relationships | AII |
| Avoiding diaper changes and contact with oral secretions from toddlers or seronegative recipients | AII |
| Preventing Disease and Disease Recurrence | |
| Ganciclovir prophylaxis or preemptive therapy based on pp65 antigenemia or DNA detection between engraftment and day 100 for patients at high risk for CMV disease | AI |
| Preferential use of preemptive therapy based on pp65 antigenemia or DNA detection between engraftment and day 100 in seronegative recipients with a seropositive donor | BII |
| CMV surveillance and preemptive therapy in CMV seropositive recipients of CD34 selected autologous transplants | BII |
| Use of IVIG or CMV-Ig for prevention of CMV infection and disease | DI |
| Use of high-dose acyclovir for prevention of CMV infection and disease in seropositive autograft recipients | DI |